Solution and solid state conformation of the human EGF receptor transmembrane region  by Rigby, Alan C. et al.
 .Biochimica et Biophysica Acta 1371 1998 241–253
Solution and solid state conformation of the human EGF receptor
transmembrane region
Alan C. Rigby, Chris W.M. Grant, Gary S. Shaw )
Department of Biochemistry and McLaughlin Macromolecular Structure Facility, The Uni˝ersity of Western Ontario, London, Ontario,
Canada N6A 5C1
Received 26 November 1997; accepted 2 February 1998
Abstract
 .The epidermal growth factor receptor EGFR is a member of the tyrosine kinase family of signalling cell surface
molecules. Signalling by this protein is mediated through binding of epidermal growth factor to its extracellular region
ultimately leading to phosphorylation of several residues on the intracellular portion of the receptor. The only means of
communication between the intracellular and extracellular domains is via the transmembrane region of the protein. In this
 .work we describe the first structural studies of a 34-residue synthetic peptide hEGFRp , representative of the human EGFR
transmembrane region, using two-dimensional and 2 H wideline NMR and CD spectroscopies. In water the peptide
demonstrated a lack of regular secondary structure and existed as oligomers. Addition of the lipomimetic solvent,
 .trifluoroethanol TFE , led to the production of monomeric structured species. Analysis of NMR spectra of the hEGFRp
indicated that an a-helix was present between residues M626 and R647. This observation was reinforced by solid state 2 H
NMR studies in lipid bilayers which showed typical ‘Pake’ spectra indicating axially symmetric motion. The helical region
in hEGFRp commences four residues later than predicted via hydrophobicity profiles, and extends to include several
charged arginine residues which would lie on the cytosolic side of the membrane. These observations provide the first
evidence that the transmembrane a-helical region in EGFR may not only traverse the membrane but may continue to the
cytosolic region near T654, an important phosphorylation site. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Many growth factors and hormones mediate bio-
logical responses through binding and activation of
cell-surface receptors. One important membrane re-
ceptor is the epidermal growth factor receptor
Abbreviations: EGFR, epidermal growth factor receptor;
hEGFRp, human epidermal growth factor receptor peptide,
residues 622–654; POPC, 1-palmitoyl-2-oleoylphosphatidyl-
choline; TFE, trifluoroethanol; CSI, chemical shift index
) Corresponding author.
 .EGFR , a member of the tyrosine kinase receptor
superfamily. This 170 kDa glycoprotein is activated
via extracellular binding of the epidermal growth
 .factor EGF . The architecture of the EGFR is a
structural blueprint for many other receptor tyrosine
w xkinases 1–5 . It possesses a glycosylated extracellu-
lar ligand binding domain of approximately 620
w xresidues which is responsible for binding EGF 6 . A
540 residue intracellular cytoplasmic domain contains
a consensus sequence typical of the tyrosine kinase
w xgene family 7–9 including an ATP binding site,
situated near the transmembrane–cytosolic interface
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of EGFR. The extra and intracellular domains of the
receptor are anchored to the plasma membrane by a
single hydrophobic transmembrane spanning region
w x9 . Allosteric regulation of ligand binding, protein
tyrosine kinase activity and ultimately, attenuation of
the EGFR is controlled by phosphorylation of T654
w x7,10 .
Type I transmembrane regions, such as the one in
the EGFR, are recognized as single hydrophobic
stretches of amino acids that traverse the hydrophobic
membrane environment. These regions provide the
only means of communication between the cytoplas-
mic and extracellular domains of the receptor. Conse-
quently, it has been suggested that receptor trans-
membrane regions may possess unique structural
andror chemical characteristics which contribute to
w xtheir mechanism of action 2 . Observations from
X-ray crystallographic analyses of multi-segment
spanning membrane proteins such as bacterio-
rhodopsin, cytochrome oxidase and the photosyn-
thetic reaction centre show that transmembrane re-
gions are usually a-helical and range from 18–36
w xamino acids in length 1,2 . A recent investigation of
glycophorin in detergent micelles has demonstrated a
w xdimeric arrangement of 23-residue a-helices 11 .
Similar information is not available for single seg-
ment transmembrane spanning proteins such as
EGFR. This has made prediction and modelling of
single transmembrane region proteins an area of in-
wtense interest with several algorithms available 12–
x15 . These approaches are very useful for prediction
of the presence and approximate location of trans-
membrane regions based on the amino acid sequence.
However, direct experimental evidence for the a-
helical nature of this region, especially at the mem-
branerfluid interface is less common. Given the im-
portance and spatial proximity of the phosphorylation
 .site T654 and the ATP binding site to this trans-
membrane region, structural information of these re-
gions would be valuable.
One approach to obtain three dimensional structure
and dynamics information of receptor proteins is to
dissect them into modules or domains. This proce-
dure has been used successfully to determine the
three dimensional structures of several intracellular
portions of receptors including the SH2 and SH3
c-src w x w xdomains from pp60 16 , Syk kinase 17 and Ab1
w x18,19 . Previous studies for transmembrane regions
have included NMR structure determinations of the
putative transmembrane regions of the neu oncogene
w x w xprotein 20 , bacteriorodopsin 21 , the S section of4
w x w xthe sodium channel protein 22 and magainin 23
using lipomimetic solvent environments. The bulk of
these studies have used peptides ranging from 18–23
residues. While this peptide length is likely adequate
to span the lipid bilayer, it allows no structural
information to be obtained for the extra or intra-
cellular regions adjacent to the membrane.
A potentially powerful approach for obtaining
structural and dynamics information about the mem-
brane spanning region in an archetypical receptor
such as the EGFR is to combine high resolution and
wideline 2H NMR methods employing synthetic pep-
tides which include the proposed transmembrane re-
gions. Other solid state NMR methods such as 15N
w x w xchemical shift tensor 24 or rotational resonance 25
can also be used. Typically, the secondary structure
of the peptide can be determined using established
two dimensional NMR techniques in a lipomimetic
environment. This information may then be used to
aid interpretation of solid state NMR data obtained
for the peptide in a lipid bilayer employing strategi-
cally placed 2H probes within the peptide. The latter
method allows orientation and mobility of the deuter-
ated peptide to be determined. These approaches have
w xbeen used elegantly by Shon et al. 26 and Nambu-
w xdripad et al. 27 in studies of the Pf1 coat protein in
detergent micelles, phospholipid bilayers and virus
particles. In the present work we have used this
approach to study a synthetic peptide indicative of
the transmembrane portion of the human epidermal
growth factor receptor comprising residues S621 to
 . 2T654 hEGFRp , including H labels at the methyl
positions of residues A623, M644 and V650. This
34-residue peptide was designed to include approxi-
mately 8–10 residues expected to reside on the cyto-
plasmic side of the membrane allowing an estimation
of the secondary structure of this region for a type I
receptor. The results of our work were also compared
to several predictive methods for the a-helical trans-
membrane region of the EGFR.
2. Materials and methods
w x .Deuterated L-methionine d -Met and perdeuter-3
w x .ated L-alanine d -Ala were obtained from Isotec4
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 . w x .Miamisburg, OH . Perdeuterated L-valine d -Val8
was purchased from Cambridge Isotope Laboratories
 .  2 .Woburn, MA . Deuterium oxide 99.9 at.% H , and
deuterated 2,2,2-trifluoroethyl alcohol-d 99.5 at.%32 .H were purchased from Isotec.
hEGFRp was synthesized using FMOC chemistry
 .by Chiron Mimotopes Clayton, Australia and stored
as a freeze dried powder. The peptide sequence was;
621 630
K -I-A-T-G-M-V-G-A- L -L-L-L-L-V-V-A-L-G-
640 650
I -G-L-F-M-R-R-R-H-I- V -R-K-R-T.
Three deuterated amino acid analogues were incor-
w x w xporated into the peptide at positions d -A623, d -4 3
w xM644, and d -V650. The synthesis of these FMOC8
w xdeuterated derivatives is described elsewhere 28 .
Peptide purification was accomplished by standard
reversed phase HPLC analysis using a Vydac protein
 .C4 column 0.46=25 cm and a 25 min linear
gradient from 0.1% phosphoric acidrH O to 0.1%2
phosphoric acidrCH CN. Elution was monitored at3
214 nm with a flow rate of 1.5 mlrmin. The purity of
the peptide was verified using analytical HPLC with
a Zorbax SB-C18 reversed phase column where
hEGFRp eluted as a single peak. hEGFRp was veri-
fied by amino acid analysis and electrospray mass
spectrometry; MW 4014.4, MW 4015.9. Thisobs calc
hEGFRp was used in all NMR and CD spectroscopic
studies.
2.1. Circular dichroism spectroscopy
CD experiments were performed using an OLIS
On-Line Instrument On-Line Instrument Systems,
.Bogart, GA equipped with a thermostatically con-
trolled cell holder stabilized by a circulating water
bath. The cell holder temperature was maintained at
238C. The spectropolarimeter was interfaced to an
IBM AT personal computer for data collection. The
sample was placed into a cell with a path length of
0.01 cm, and spectra were recorded between 195 and
250 nm. The spectropolarimeter was routinely cali-
brated before data collection with D-10-camphor-
 .sulfonic acid CSA , at 192.5 and 290.5 nm.
CD experiments were carried out for a variety of
TFE:H O conditions. Initial studies utilized a stock2
solution of approximately 764 mM hEGFRp in 300
ml of TFE. This stock solution was used to create a
series of dilutions, which varied from 100% TFE to
20% TFE. Similar experiments were performed using
H O as the initial solvent and encompassed a solvent2
range of 100% H O to 20% H O. The concentrations2 2
of the actual samples where spectra were acquired
ranged from 23.2"3.3 mM for the 100% TFE sam-
ple to 23.9"3.1 mM for the 40% H O sample as2
determined from amino acid analyses performed in
triplicate. During data acquisition, the total sample
absorbance was maintained less than 1 to maximize
w xthe signal to noise ratio 29 . In all experiments a
blank spectrum for the same percentage of TFErH O2
was acquired and used for baseline correction. The
percentage of a-helix in hEGFRp was determined
using equation,
ik
u s f y u H lHl 0 /N
w xwhere u is the observed helicity at 222 nm, f isl H
the fraction of the peptide that is helical, i represents
the number of helical segments, k is the wavelength
dependent constant of 2.6 at 220 nm, N is the total
w xnumber of residues within the peptide, and u isH l0
w xthe ellipticity for an a-helix of infinite length 30 .
2.2. NMR spectroscopy
Purified hEGFRp was dissolved in a variety of
solvent mixtures of H O, D O and TFE-d . Initial2 2 3
 .experiments used hEGFRp 2.1 mg dissolved in 500
ml 99.9% D O at a pH of 7.09 uncorrected meter2
.reading . To optimize NMR spectra the peptide was
also dissolved in various ratios of TFE and H O, and2
the pH was altered from acidic conditions at pH 2.3
to basic conditions at pH 9.1 and vice versa via the
addition of NaO2H or 2HCl. For two dimensional
experiments, 2.1 mg of hEGFRp was dissolved in
375 ml TFE and 125 ml H O added. The solution2
was adjusted to a final pH of 6.16. For 2H NMR
studies, lipid bilayers containing hEGFRp were pre-
w xpared as previously described 28 . Briefly, the pep-
tide was dissolved in TFE and the appropriate amount
of POPC added to a peptide:POPC ratio of 3:50. The
solvent was removed and the residue rehydrated in 30
mM HEPES containing 20 mM NaCl and 5 mM
EDTA in deuterium-depleted water at pH 7.2.
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Fig. 1. Circular dichroism spectra of hEGFRp at a variety of
H OrTFE concentrations at 258C, pH 7.09. hEGFRp was ini-2
tially dissolved in TFE to a concentration of 764 mM and then
diluted to final concentrations of 23–24 mM with either H O or2
TFE to the desired H O:TFE ratio. The spectra represent the2
 .following ratios of H O:TFE; 100% H O , 60%2 2
 .  .H Or40% TFE - - - - , 40% H O:60% TFE – – – , 20%2 2
 .  .H O:80% TFE - - - - - - and 100% TFE .2
1H NMR spectra were acquired on a 500 MHz
Varian Unity spectrometer. All spectra were refer-
enced to internal DSS at 0.0 ppm. Typical acquisition
parameters for one dimensional spectra were, acquisi-
tion time, 2.0 s; spectral window, 6000 Hz; 908 pulse
width, 11.5 ms and 1024 transients. Phase-sensitive
w x w xDQF-COSY 31 , TOCSY 32,33 and NOESY spec-
tra were collected using 64 transients and 512 com-
plex data points in F and 256 increments in F2 1
yielding acquisition times of 0.171 s in t and 0.0432
s in t . TOCSY spectra were collected for 30 and 501
w xms mixing times. NOESY spectra 34 were recorded
w xin the hypercomplex mode 35 for mixing times of
150, 300, and 400 ms. In all experiments, residual
HDO was suppressed with a weak 2.0 s presaturation
pulse. Spectra were processed using the program
 .Vnmr Varian on a Silicon Graphics XS24 worksta-
tion using either sine-bell or pr8 shifted sine-bell
weighting functions, with baseline correction in the
F dimension.2 2H NMR spectra were acquired at 76.7 MHz using
the quadrupolar echo sequence without composite
pulses. Typically, 5.2 ms 908 pulses were used with
30 ms delays between pulses and prior to acquisition.
A 100 ms recycle delay was used. The spectral
window was 100 kHz and data was processed using
100 Hz line broadening.
3. Results
The 34-residue hEGFRp comprised residues I622-
T654 from human EGFR with residue S121 replaced
by K. It included the proposed membrane spanning
region, residues I622-M644, and also T654, the site
of phosphorylation by protein kinase C. The N-termi-
nal residue, K621, was biotinylated for use in future
studies. For 2H NMR studies, deuterated amino acids
were incorporated at positions A623, M644 and V650
using analogues deuterated at the methyl groups in
 .Fig. 2. Effect of TFE on u of circular dichroism spectra v222
and on peakwidths of selected resonances in 1H NMR spectra
 .‘ . The plot shows the observed u for a given TFE concen-222
 .tration for hEGFRp at 258C, pH 7.09 left . Peakwidths were
measured as a function of % TFE using the aliphatic methyl
region of the spectra centred about 0.96 ppm for a 1 mM
 .hEGFRp sample in D O, pH 7.09, 258C right .2
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each amino acid. Based on hydropathy analysis, this
should place residues A623 and M644 near the lipid
bilayer surfaces and residue V650 beyond the sur-
face. An important aspect of this work was to define
the secondary structure of the peptide in the bilayer
and in the cytosolic region adjacent to the membrane.
This can not be determined by conventional 2H NMR
spectroscopy alone. As a stepping stone towards these
studies, the conformation of the hEGFRp was ini-
tially determined using high resolution NMR tech-
niques in a lipomimetic solvent.
3.1. Production of a monomeric hEGFRp species
In solution, hydrophobic membrane-spanning pep-
tides such as the hEGFRp tend to be insoluble or
aggregate—the aggregates frequently being com-
posed of unfolded forms of the peptide or multimeric
b-sheet like structures in which the secondary struc-
w xture likely does not represent the native fold 36,37 .
Our initial studies of hEGFRp focused on the produc-
tion of a monomeric form of the peptide in solution
and in lipid bilayers. This step was essential since it
was important to establish a method which preserved
the native peptide secondary structure while produc-
ing a molecular co-dispersion with lipid. The sec-
ondary structure of hEGFRp was determined in solu-
tion so this information could be used in solid state
w xanalyses 28 .
Although hEGFRp contains 20 hydrophobic
 .residues of 34 total , it was found to be water
 .soluble over a broad pH range 2.3–9.1 . High reso-
lution 1H NMR spectra of 1 mM solutions of the
 .peptide data not shown were characterized by broad
linewidths, independent of the pH and affected little
by temperature. hEGFRp was subsequently found to
dissolve rapidly in the organic solvent trifluo-
 .roethanol TFE which has been pioneered by Gullick
Fig. 3. Region of the 500 MHz TOCSY spectrum showing correlations between NH protons and other intraresidue protons for a mixing
time of 50 ms. Data was acquired using 1.0 mM hEGFRp in 75% TFE:25% H O, pH 6.16 at 378C. Spin systems are identified near the2
NH a correlation for each residue and through bond connectivities indicated by lines. Some spin systems cannot be identified at this
contour level.
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w x w x w xet al. 20 , Mulvet et al. 22 , and Norwood et al. 38
to study hydrophobic peptides including those de-
rived from other membrane proteins. Unlike the
aqueous samples, it provided 1H NMR spectra with
 .narrow linewidths 7–10 Hz similar to those ob-
w xtained for other 34-residue peptides 39 . Conve-
niently, TFE also dissolved the lipids of interest for
solid state work as has been previously shown by
w xOpella et al. 40 . These qualities made TFE the
medium of choice for characterization of the solution
structure of the transmembrane hEGFRp and prepara-
tion and characterization of the peptide in lipid bilay-
ers.
To better quantify the 1H NMR observations de-
scribed above, the secondary structure of hEGFRp
was studied by CD spectroscopy in lipomimetic envi-
ronments comprised of various ratios of TFE and
H O. The resulting CD spectra for these experiments2
are shown in Fig. 1. The spectrum of hEGFRp in an
aqueous environment showed a negative band at 200
nm indicative of an unstructured peptide in aqueous
solution. As the proportion of TFE was increased the
Table 1
1H chemical shift data for the hEGFRpa
Residue NH a CH bCH g CH Others
Biotin 4.35, 4.56, 2.96, 3.23
K621 7.73 4.36 1.95, 1.80 1.51 « H:2.38
XI622 7.54 4.17 1.92 1.53 g 1.22, d 0.96
 .A623 d-4 7.88
T624 7.78 4.17 4.34 g 1.29
G625 8.06 3.97, 4.01
M626 7.95 4.47 2.19 2.60, 2.68
YV627 7.74 3.86 2.19 g 1.09, g 1.00
G628 7.97 3.86
A629 7.60 4.18 1.54
XL630 7.75 4.00 1.99, 1.85 1.78 d 1.10, d 0.94
XL631 7.99 4.17 1.85, 1.82 1.66 d 1.02, d 0.93
XL632 7.61 4.14 1.83, 1.68 1.78 d 1.12, d 0.93
XL633 7.77 4.30 1.92, 1.70 1.54 d 1.30, d 0.95
XL634 8.02 4.21 1.96, 1.83 1.65 d 0.98, d 0.93
XV635 8.22 3.75 2.39 g 1.14, g 1.02
XV636 8.34 3.76 2.29 g 1.12, g 0.99
A637 8.51 4.18 1.60
XL638 8.65 4.24 1.97, 1.68 1.88 d 1.15, d 0.93
G639 8.21 4.01, 3.90
XI640 8.57 3.97 2.04 1.85, 1.22 g 1.02, g 0.88
G641 8.29 3.97, 3.86
XL642 8.36 4.17 1.94, 1.85 1.59 g 1.14, g 0.93
F643 8.23 4.28 3.43, 3.35 d 7.28, « 7.42, z 7.34
 .M644 d-3 8.78 4.26 2.40, 2.14
R645 8.07 4.17 2.01, 1.85 1.71 d 3.20
R646 8.09 4.12 1.94, 1.93 1.82, 1.70 d 3.15
R647 7.87 4.02 1.94, 1.83 1.72, 1.50
2 4H648 7.83 4.47 3.28, 3.17 H 7.65, H 7.42
I649 7.75 4.08 1.97 1.24, 1.10 g 0.94
 .V650 d-8 8.05
R651 7.75 4.17 1.87, 1.75 1.67, 1.54
K652 7.88 4.34 1.92, 1.83 1.49 d 1.77, 1.72
R653 8.06 4.44 1.99, 1.85 1.71
T654 7.52 4.18 4.24 g 1.19
aReferenced to DSS at 0 ppm in 75% TFE:25% H O at 378C.2
b w x w x w xDeuterated amino acid residues are d -A623, d -M644 and d -V650.4 3 8
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band intensities at 208 and 222 nm increased in
magnitude and the spectrum of hEGFRp in 100%
TFE was characteristic of a peptide with a significant
proportion of a-helix present. It was also apparent
that the CD spectra at 60–100% TFE were very
similar having u sy16485"740 deg cm2 dmy1.222
These results are summarized in Fig. 2 by a smooth
transition from minimum magnitude of u at 100%222
H O to a maximum amplitude at 60–100% TFE. An2
isodichroic point near 203 nm was observed consis-
tent with a two-state coil-helix transition for the
w xpeptide as the amount of TFE was increased 41 .
Experiments involving similar solvent ratios of
TFE and H O were also performed using 1H NMR2
spectroscopy although at about 50-fold higher con-
centrations than CD spectra. An initial 1 mM hEGFRp
sample was prepared in TFE, titrated with H O, and2
peakwidths were measured as a function of % TFE
 .Fig. 2 . At low TFE concentrations all resonances
were very broad. Due to this excessive broadening of
the peaks, the cluster of resonances in the methyl
region was measured as a function of % TFE, rather
than any individual peak. At the higher TFE concen-
 .trations )50% , the spectral lines exhibited minimal
Fig. 4. NH,NH region from the 150 ms NOESY spectrum of 1.0 mM hEGFRp in 75% TFE:25% H O, pH 6.16 and 378C. Sequential2
 .d i,iq1 connectivities are traced from M626 to R647. For regions where peaks are congested, spectra were acquired at 258C to shiftNN
several resonances and facilitate correlations.
( )A.C. Rigby et al.rBiochimica et Biophysica Acta 1371 1998 241–253248
shifting and had approximately the same peakwidth
 .Fig. 2 of 37.6"1 Hz. It is clear from this data that
a decrease in peakwidth for hEGFRp parallels an
increase in magnitude of u over similar aqueous222
TFE combinations.
3.2. Structure of hEGFRp in lipomimetic media
Both CD and 1H NMR titration experiments
showed that aqueous solutions containing )60%
TFE were an optimal membrane-mimetic medium
where the hEGFRp was soluble. This combination
possessed a high non-polar content to mimic a lipid
environment and some aqueous component to mimic
the extracellularrcytosolic environments. This was
important because the entire hEGFRp sequence was
not expected to lie in the membrane but rather 8–10
residues were expected to reside in the aqueous cyto-
plasm. Consequently, the hEGFRp was prepared in
 .an aqueous 75% TFE vrv medium at pH 6.16 for
further 1H NMR characterization.
The sequential assignment of the hEGFRp was
accomplished using a variety of standard two-dimen-
w xsional NMR techniques 42,43 . In the ‘finger print’
region of the DQF–COSY spectrum, 29 out of a
possible 32 residues were observed. Crosspeaks ex-
pected for A623 and V650 were absent due to deuter-
ation at the a carbon site. A TOCSY spectrum, Fig.
3, allowed the identification of intraresidue connec-
tivities, and proved valuable for residues which had
extended sidechains such as I622, V627, V635, and
V636. The sequential assignment of the hEGFRp
used spin system assignments from TOCSY spectra
and a 300 ms NOESY spectrum. Table 1 provides the
chemical shifts of the 1H resonances assigned for the
hEGFRp.
The secondary structure in the hEGFR peptide was
determined from the identification of a large number
 .  .  .of d i,iq1 , d i,iq3 and d i,iq3 con-NN a N a b
nectivities. Fig. 4 shows the d region from the 150NN
ms NOESY spectrum of hEGFRp indicating a con-
tiguous stretch of nOes from M626 to R647. The data
shows many well resolved resonances between 8.0–
8.8 ppm with many intense NH–NH connectivities.
Several closely spaced NH resonances between 7.9–
8.0 ppm made analysis of connectivities in this region
difficult at 378C. However, at 258C some of these
overlapping peaks were well resolved allowing un-
Fig. 5. Amino acid sequence and summary of NOE data for the
hEGFR peptide taken from 150 ms NOESY spectra. The thick-
ness of the various lines corresponds to the approximate intensity
of the measured NOE. NOEs that can not be unequivocally
identified due to resonance degeneracy are indicated with dashed
3 .lines. Backbone coupling constants J were measured fromHNa
DQF–COSY spectra for resolved resonances. Coupling constants
 .  .are indicated for -6 Hz fl and 6–8 Hz ( . No coupling
constants )8 Hz were observed. CSI refers to the chemical shift
w xindex 44 for a CH resonances, except A623 and V650 which
are a-deuterated.
ambiguous identification. In addition, stretches of
 .  .d i,iq3 and d i,iq3 connectivities wereaN a b
identified between residues G625 and R647, Fig. 5.
Many of these residues also exhibited 3J -6 HzHNa
consistent with an a-helical structure present in this
region. Use of the CSI for a CH resonances showed a
systematic pattern of upfield shifted resonances rela-
tive to random coil values also indicative of a-helix
w xformation 44 . The exception to this was the small
sequence, G–I–G, whose a CH chemical shifts
showed no preference for regular secondary structure
 .although characteristic d i,iq3 crosspeaks wereaN
observed.
3.3. 2H NMR analysis of hEGFRp in lipid bilayers
With an a-helical secondary structure between
M626 and R647 defined in hEGFRp, it was now
important to apply this information to the placement
of hEGFRp in a synthetic membrane environment.
The hEGFRp was incorporated into POPC lipid bi-
layers and the resulting assemblies studied by 2H
NMR spectroscopy, Fig. 6. A first method utilized
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Fig. 6. Regions of the 2H wideline NMR spectra of hEGFRp in
POPC including 30 mM HEPES buffer, 20 mM NaCl and 5 mM
EDTA at 308C and pH 7.2. The peptide was assembled into
unsonicated bilayers of POPC at a peptiderlipid molar ratio of
3:50. Spectrum A shows the 2H NMR spectrum obtained from a
sample prepared by detergent dialysis as described in the text.
Spectrum B shows the 2H NMR spectrum obtained from a
sample prepared from hydration of a thin film generated by
removal of solvent from peptiderlipid solutions in TFE. In
spectrum B, the quadrapolar splittings for A623 bCH 6.23
.  .  .kHz , V650 g CH 5.6 kHz , M644 « CH 3.2 kHz and Val3 3
 .g CH 1.2 kHz are indicated above the Pake pattern as deter-3
w xmined from labelling of the individual residues 28 .
traditional aqueous detergent dialysis and yielded a
 .spectrum Fig. 6A which was broad and featureless.
In a second method, using an approach similar to
preparation of high resolution NMR samples,
hEGFRp was dissolved first in TFE and then POPC
added to the solution. A similar method has been
w xpreviously described by Opella et al. 40 . In contrast
to the detergent dialysis method, removal of the
solvent and subsequent rehydration yielded a more
 .conventional ‘Pake’ spectrum Fig. 6B representa-
tive of axially symmetric motion of the hEGFRp
about an axis near to or perpendicular to the bilayer.
Similar 2H spectra have been shown for gramicidin
w x w x45,46 and the fd coat protein 47 containing deuter-
ated methyl groups. The 2H NMR spectrum of
hEGFRp resulted from deuterium labels at A623
 .  . a CD, bCD , M644 « CD and V650 a CD,3 3
X .bCD and gg CD . As indicated in Fig. 6B the3
quadrupolar splittings for the deuterated methyl
groups for A623, M644 and V650 were intense and
well resolved. Unambiguous assignment of these Pake
doublets were made using a series of monodeuterated
w xpeptides 28 . Under these conditions, the largest
observed splitting was 6.2 kHz arising from the A623
b-CH . The « CH for M644 had a splitting of 3.23 3
kHz and the non-degenerate g CH groups for V6503
had splittings of 5.6 and 1.2 kHz.
4. Discussion
The observation that hEGFRp is soluble in aque-
ous solution is interesting given the hydrophobicity
of the peptide. This solubility likely arises from the
high density of positively charged residues near the
C-terminus especially at pH-7. Under these condi-
tions, hEGFRp exists in a highly aggregated form as
judged by NMR spectroscopy which yielded broad
featureless resonances. This is supported by the in-
 .creased linewidths in hEGFRp )20 Hz compared
 .to monomeric peptides 8–10 Hz of a similar size
w x39 . hEGFRp is mostly unstructured in aqueous solu-
tion, having a CD negative intensity at u , little200
 2 y1.evidence for a-helix u )y5000 deg cm dm222
 2 y1.or b-sheet u )y8000 deg cm dm , and no215
NH or a CH resonances downfield of 9 ppm or 5
ppm, respectively. Consistent with these results the
lack of quadrupolar splitting in the 2H NMR spec-
trum of hEGFRp in POPC when prepared from
.aqueous solutions is indicative of non-axially sym-
metric motion arising from a disordered or aggre-
gated form of the peptide. These observations are in
agreement with other studies which show many hy-
drophobic peptides form aggregated complexes in
w xaqueous solution 36 .
4.1. hEGFRp is helical in solution and bilayers
In a lipomimetic environment comprised of aque-
ous TFE, hEGFRp forms a monomeric, a-helical
structure as determined from CD and NMR data. TFE
was the solvent of choice for these studies because it
is known to stabilize the formation of a-helices in
peptides which have the propensity to form an a-helix
w x48–50 such as transmembrane regions and it has
( )A.C. Rigby et al.rBiochimica et Biophysica Acta 1371 1998 241–253250
recently been demonstrated to be selective in that it
will not induce or impose secondary structural re-
straints on regions that are normally unstructured in
w xproteins 51–53 . For hEGFRp the percentage of
a-helix plateaued at approximately 60% TFE. Since
no further increase in u was observed within222
.experimental error at TFE concentrations greater
than 60%, these findings suggest that TFE does not
induce additional a-helix formation in regions of the
peptide that are unstructured or would not normally
w xform a helical segment 49,51–53 . Analysis of the
CD data shows approximately 19 of the 34 residues
form a contiguous a-helix in hEGFRp in this
lipomimetic environment. Under similar conditions
NMR data shows an a-helix comprising 22 residues
and spanning positions M626 to R647 in hEGFRp.
 .In POPC bilayers prepared from TFE solutions
the 2H NMR spectrum of hEGFRp exhibits a typical
‘Pake’ pattern. The nature of this pattern is character-
istic of a peptide adopting an a-helix in bilayers and
undergoing axially symmetric rotation as has been
w x w xobserved in gramicidin 45,46 , fd coat protein 47
w xand Pf1 protein 26 . This observation indicates that
the a-helical nature of hEGFRp in 60% aqueous TFE
is representative of the secondary structure found in
bilayers. The magnitude of the quadrupolar coupling
 .constant for A623 bCD 6.2 kHz is larger than3
expected for mobile alanine residues undergoing
isotropic motion as observed in 2H NMR studies of
w xthe fd helical coat protein near the N-terminus 54 .
However, it is also greater than that expected for a
stable helical conformation oriented perpendicular to
the bilayer where an A623 a C–bCD angle of about3
568 with the helical long axis would occur Dnf1.4
.kHz . This would indicate that although helical,
hEGFRp may adopt an orientation near A623 some
108 from the bilayer normal in a fashion more remi-
niscent of that found in the neu transmembrane re-
w xgion 24 . Alternatively, it is possible that the confor-
mation of A623 in lipid bilayers is an average of
multiple conformations in agreement with solution
NMR data which indicates this region is not clearly
a-helical.
4.2. Location of the EGFR transmembrane helix
 .The a-helix length 26 residues and location
 .M626–R647 in hEGFRp were compared with struc-
Table 2
Transmembrane regions of EGFR
Method Positions No. of residues
This work M626–R647 22
w xJones et al. 15 I619–F643 25
aw xPersson and Argos 14 S621–I640 20
bw xRost et al. 12,13 I622–M644 23
T624–G641 18
Hydropathy I622–M644 23
cw xTmBASE 67 G625–M644 20
dSOSUI S621–M644 24
ew xDAS 68 G625–L642 18
ahttp:rrwww.embl-heidelberg.dersspredrssp_sin.html.
bhttp:rrwww.embl-heidelberg.derpredictproteinrpredictpro -
tein.html.
chttp:rrulrec3.unil.chrsoftwarerTMPRED_form.html.
dhttp:rrwww.tuat.ac.jpr ;mitakiradv_sosui.
ehttp:rrwww.biokemirsurser;serverrDAS.
tural predictions for the a-helix membrane spanning
 .region of EGFR Table 2 and general observations
for type I membrane spanning protein sequences. In
general, the length of the a-helix observed from
 .NMR data 26 residues is longer than most predic-
 .tive methods 18–23 residues which predict only the
membrane spanning region. This indicates that some
a-helix must be found outside the membrane envi-
ronment.
Examination of our data and Table 2 reveals the
location of the transmembrane region of hEGFRp.
Both NMR analysis and a majority of predictive
methods indicate the region between M626 and M644
is helical and spans the membrane. A majority of the
predictive methods indicate M644 is the terminating
helical residue. In agreement with this, a preference
 .for phenylalanine residues F643 has been noted
w x14,55–57 at the interior membrane interface of type
I transmembrane proteins. High resolution NMR ob-
servations show that hEGFRp is a-helical in this
region satisfying hydrogen bonding requirements for
the predicted portion of the transmembrane helix.
Most predictive methods indicate the a-helical
transmembrane region in the EGFR includes I622 at
the N-terminus. This is earlier in the sequence than
 .identified by NMR methods M626 and shows some
ambiguity exists in this region. This supports obser-
vations from the present 2H NMR studies which
showed axially symmetric motion, as would be ob-
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served for an a-helix, but were inconclusive for
orientation. In agreement with this, previous studies
from computational conformational analysis of EGFR
and related peptides show a non-helical preference
w xfor regions A624–G625 and V627–G628 58,59 .
Further, analysis of type I membrane spanning se-
quences suggests that P620 and S621 K621 in
.hEGFRp lie outside the membrane while threonine
 .T624 is usually not found in a-helical membrane
spanning regions but is more characteristic of an
w xN-capping residue 56 . In addition, EGFR does not
have any acidic amino acids near this region which
may also be important for helix dipole stabilization
w x60 , although this has been noted for other type I
w xmembrane spanning proteins 57 .
Alternatively, the a-helix in hEGFRp may be trun-
cated at the N-terminus compared to that predicted
because the length of peptide does not provide suffi-
cient i,iq4 hydrogen-bonding to maintain the a-
helix for residues K621–T624. Similar observations
have been made in high resolution studies of the neu
protein and magainin where the first and last 3–4
w xresidues are not helical 22,23 . As has been pointed
w xout by Reithmeier 57 , an a-helical transmembrane
segment would need to extend for one complete turn
outside the membrane to satisfy all hydrogen bonding
requirements.
4.3. E˝idence for a cytoplasmic helix
The 34-residue length of hEGFRp is longer than
would typically traverse a bilayer allowing a struc-
tural examination of the region at the membrane–cy-
tosol interface. While a majority of the transmem-
brane predictive methods provide M644 as the trans-
membrane helix terminating residue, it is interesting
that residues M644–R647 in hEGFRp are a-helical
in a lipomimetic medium. Based on transmembrane
 .spanning predictions Table 2 this region would lie
to the cytosolic side of the membrane. The three
sequential arginine residues at positions R645, R646
and R647 are consistent with the positive inside rule
for type I transmembrane sequences acting as a stop
w xtransfer signal for membrane insertion 2,56,61,62 .
In addition, the position of the arginine residues in
the helix agrees with a preference for basic residues
w xnear the C-cap of an a-helix 60 acting to neutralize
w xthe helix dipole 63–65 .
In POPC bilayers, wideline 2H NMR spectra indi-
cate the « CH group of M644 has a very small3
 .quadrupolar coupling constant 3.2 kHz indicating
its motion is not isotropic. This is consistent with the
solution NMR results indicating an a-helix in this
region. The magnitude of the coupling constant likely
results from reorientation about the Ca–Cb , Cb–Cg
and Cg–S bonds yielding a more mobile side chain
and is similar to that noted in bacteriorhodopsin for a
w xsurface exposed methionine 66 . Together, these re-
sults support methods predicting M644 has a helical
backbone conformation and resides at the mem-
branerfluid interface.
Solution NMR data indicates the a-helical struc-
ture of hEGFRp ends shortly before V650 at position
R647. Supporting this, wideline 2H NMR results for
V650 provide coupling constants of 5.6 and 1.2 kHz
for the two non-degenerate g CD groups indicating3
that backbone and sidechain motion is not isotropic
as would be expected from rapid reorientation of this
residue in solution. However, there is no indication of
a large coupling constant similar to those observed
for interior membrane spanning residues of grami-
 .cidin 26–27 kHz for valines suggested to be in a
fixed rotameric state on a rigid backbone frame
w x45,46 . Rather, the d CD splittings for V650 are3
more reminiscent of observations for V1 in grami-
cidin where it was suggested that ‘wobbling’ of the
peptide about an axis perpendicular to the bilayer
occurs in addition to three-site flipping of the g CD3
groups between a preferred conformation at x s18081
w xand conformers at x s"608 45,46 . In this respect1
it would be useful to have dynamics information
about the backbone region of V650 to identify
whether an a-helix is extended past R647 or whether
the observed quadrapole coupling is a result of back-
bone and sidechain motional averaging as observed
in solution NMR data.
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